|
Group
|
DSS
| |
OS
| |
|---|
|
HR (95% CI)
|
P
|
HR (95% CI)
|
P
|
|---|
|
Age (>60 years vs ≤60 years)
|
1.82 (0.86-3.85)
|
NS
|
2.02 (1.17-3.52)
|
0.012
|
|
Size (>20 mm vs ≤20 mm)
|
1.82 (0.91-3.64)
|
NS
|
1.44 (0.89-2.32)
|
NS
|
|
LN (positive vs negative)
|
2.54 (1.59-4.06)
|
<0.0001
|
2.05 (1.51-2.80)
|
<0.0001
|
|
Grade (III vs I, II)
|
1.18 (0.80-1.74)
|
NS
|
1.24 (0.95-1.62)
|
NS
|
|
ER status (positive vs negative)
|
1.23 (0.82-1.84)
|
NS
|
0.95 (0.69-1.32)
|
NS
|
|
PR status (positive vs negative)
|
0.59(0.41-0.86)
|
0.006
|
0.82 (0.60-1.10)
|
NS
|
|
Radiation (yes vs no)
|
0.79 (0.41-1.55)
|
NS
|
0.76 (0.47-1.22)
|
NS
|
|
Surgery (yes vs no)
|
0.39 (0.16-0.96)
|
0.041
|
0.57 (0.27-1.20)
|
NS
|
- DSS, disease-specific survival; OS, overall survival; NEC; neuroendocrine carcinoma; HR, hazard ratio; CI, confidence interval; NS, not significant; LN, lymph node; ER, estrogen receptor; PR, progesterone receptor.
